Safety and Efficacy Study of Doxycycline in Combination With Interferon-B-1a to Treat Multiple Sclerosis

Phase 4 Completed 16 enrolled Louisiana State University Health Sciences Center Shreveport Biogen · collab

NaSingle-groupOpen-labelTreatment

Summary

To evaluate the efficacy, safety, and tolerability of combination therapy with intramuscular interferon beta-1a and oral doxycycline, a potent inhibitor of matrix metalloproteinases, in patients with relapsing remitting multiple sclerosis (RRMS) having breakthrough disease activity.

Timeline

Start: 2003-12
Primary completion: 2009-08
Completion: 2009-10

Publications

Results Minagar A, Alexander JS, Schwendimann RN, Kelley RE, Gonzalez-Toledo E, Jimenez JJ, Mauro L, Jy W, Smith SJ. Combination therapy with interferon beta-1a and doxycycline in multiple sclerosis: an open-label trial. Arch Neurol. 2008 Feb;65(2):199-204. doi: 10.1001/archneurol.2007.41. Epub 2007 Dec 10.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Doxycycline	Small molecule	100 mg	Oral
Background	Interferon beta-1a	Protein / enzyme biologic	30 ug	Intramuscular

Safety and Efficacy Study of Doxycycline in Combination With Interferon-B-1a to Treat Multiple Sclerosis

Summary

Timeline

Publications

Drugs

Indications